Clinical trial · Interventional
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
NCT07154264CI-TRIAL-00115404recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DZD8586 | Drug | — | UNRESOLVED |
| Venetoclax | Drug | Venetoclax | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Combination of DZD8586 and Venetoclax
- description
- DZD8586 will be taken orally once daily on days 1-28 of each cycle. Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.
- interventionNames
- Drug: DZD8586
- Drug: Venetoclax
Primary outcomes (2)
- measure
- Part A: Incidence of Adverse Events
- timeFrame
- 30 days after the last dose
- measure
- Part B: 2-year progression free survival (PFS) rate assessed by investigator
- timeFrame
- Approximately 5 years
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male and female ≥ 18 years of age. 2. ECOG performance status 0-2, and life expectancy ≥ 6 months. 3. Confirmed newly diagnosis or treatment naïve CLL/SLL with indication for treatment. 4. Patients with SLL must have at least one measurable lesion. 5. Adequate bone marrow reserve and organ functions. 6. Willing to comply with contraceptive restrictions. Exclusion Criteria: 1. Any of previous or current treatment prohibited by protocol. 2. Any unresolved \> grade 1 drug-related adverse events. 3. Known or suspected Richter's transformation, or prolymphocytic leukemia. 4. CNS involvement. 5. Active infection. 6. Any of severe cardiac or pulmonary abnormalities. 7. Poorly controlled autoimmune anemia or autoimmune thrombocytopenia. 8. Poorly controlled gastrointestinal disorder, inadequate absorption of medication or other systemic diseases. 9. Prior malignancy within the past 3 years. 10. Known allergy to study drugs, any of the ingredients of the study drugs, or xanthine oxidase inhibitors or rasburicase.
References
Publications (0)
Data not yet available
No reference posted for this study.